Fig. 1

THBS1 is a marker of high-grade glioma. a Immunohistochemistry (IHC) of THBS1 in patient samples from grade II astrocytomas and oligodendrogliomas (upper panels), grade III anaplastic astrocytomas and anaplastic oligodendrogliomas (middle panels) and grade IV glioblastomas (lower panels). Magnification of tumour areas is shown in each panel on the right hand side. Scale: 50 µm. Quantification of THBS1 staining by IHC profiler from Fiji software. A, astrocytomas (n = 5); O, oligodendrogliomas (n = 5); AA, anaplastic astrocytomas (n = 5); AO, anaplastic oligodendrogliomas (n = 5); and GBM, glioblastomas (n = 5). The graph represents the results as means ± s.d. **P < 0.01; ***P < 0.001; ****P < 0.0001; ns not significant (ANOVA). b Quantification of THBS1 staining by using tissue microarrays. 121 patients were analysed using TMA (Biomax), and IHC with anti-THBS1 antibodies. 57 were of grade II, 27 of grade III and 37 of GBM–grade IV. The graph represents the results as means ± s.d. **P < 0.01; ****P < 0.0001 (ANOVA). c Left panels: immunofluorescence stainings of CD31 (red) and Nestin (green) of a P3 tumour section. Images below represent core and invasive areas. Scales: 500 µm (upper panel) and 20 µm (lower panels). Right panels: IHC for THBS1 in samples representing core and invasive areas in P3 tumours, counterstained with haematoxylin. THBS1 is expressed in invasive areas of P3 tumours. Scale: 50 µm